Human endogenous retrovirus type W envelope protein (HERV-W Env (also commonly referred to as Syncytin-1))

The **human endogenous retrovirus type W envelope protein** is a fusogenic glycoprotein encoded by the env gene within the HERV-W family. The most well-characterized member is **Syncytin‑1**, which plays an essential physiological role in human placental development by mediating trophoblast fusion into syncytiotrophoblasts through interaction with amino acid transporters ASCT1 (SLC1A4) and ASCT2 (SLC1A5)[3][5]. Beyond its normal function, aberrant expression has been implicated in several diseases. In multiple sclerosis, it induces pro-inflammatory cytokine release via toll-like receptor 4 activation on immune cells—contributing to demyelination—and inhibits oligodendrocyte precursor differentiation, exacerbating neurodegeneration [2][3][7]. Elevated expression has also been observed during certain infections such as SARS-CoV‑2/COVID‑19 where it correlates with disease severity [4], as well as various cancers where it may promote tumor progression through enhanced cell fusion [6]. As an ancient viral remnant co-opted into human physiology but reactivated under pathological conditions, it represents both a unique therapeutic target and a complex safety challenge due to its dual roles.

Other names

Syncytin-1HERV-W EnvERVWE1 envelope proteinHuman endogenous retrovirus W envelope glycoprotein

For experimental drugs/antibodies targeting this molecule: – Neutralization of the fusogenic activity of the envelope protein to prevent pathological cell fusion. – Inhibition of pro-inflammatory signaling induced by interaction with toll-like receptor 4. – Blockade of interaction with its cellular receptors ASCT1/SLC1A4 or ASCT2/SLC1A5 to prevent downstream effects on neural or immune cells.